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Results After 6 months, dual-task-related cadence 
increased in the IG compared to the CG (p = 0.019, 
d = 0.71). No significant changes, but GBE-associated 
numerical non-significant trends were found after 6-month 
treatment for dual-task-related gait velocity and stride time 
variability.
Discussion Findings suggest that 120 mg of GBE twice-
daily for at least 6  months may improve dual-task-related 
gait performance in patients with MCI.
Conclusions The observed gait improvements add to the 
understanding of the self-reported unspecified improve-
ments among MCI patients when treated with standardised 
GBE.
Keyword Gait · Walking · Executive function · Mild 
cognitive impairment · Cognitive enhancer · Ginkgo biloba 
extract
Introduction
Safe and efficient gait is crucial for mobility, independ-
ence and quality of life in older people [1]. For decades, 
it was generally considered that gait was regulated at the 
spinal level. The development of neuroimaging (e.g. mag-
netic resonance imaging) and electrophysiological tech-
nologies (e.g. transcranial magnetic stimulation) have 
led to a greater understanding of the neuro-motor control 
of gait. It has been recently reported that frontal and cen-
tral brain regions, specifically executive functions which 
depend upon the integrity of the prefrontal cortex, play a 
key role in gait control during single and dual-task walk-
ing [2, 3]. In cognitive disorders, such as mild cognitive 
impairment (MCI) and dementia, executive functions, and 
thus gait control are impaired [4]. Studies suggest that the 
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Background In patients with mild cognitive impairment 
(MCI), gait instability, particularly in dual-task situations, 
has been associated with impaired executive function and 
an increased fall risk. Ginkgo biloba extract (GBE) could 
be an effective mean to improve gait stability.
Aims This study investigated the effect of GBE on spatio-
temporal gait parameters of MCI patients while walking 
under single and dual-task conditions.
Methods Fifty patients aged 50–85  years with MCI and 
associated dual-task-related gait impairment participated in 
this randomised, double-blind, placebo-controlled, explora-
tory phase IV drug trial. Intervention group (IG) patients 
received GBE  (Symfona® forte 120  mg) twice-daily for 
6 months while control group (CG) patients received pla-
cebo capsules. A 6-month open-label phase with identical 
GBE dosage followed. Gait was quantified at months 0, 3, 
6 and 12.
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administration of cognitive enhancers might be effective in 
improving both, executive functions and gait performance 
[5].
Currently, there is limited knowledge about efficient 
drug interventions in older people with MCI [6]. A recent 
meta-analysis of 2625 patients with dementia showed that 
treatment with Ginkgo biloba extract (GBE) 120 or 240 mg 
daily over 22 weeks can improve cognition and activities of 
daily living [7]. In vitro and in vivo studies have described 
modes of GBE action which include vasomodulatory/vaso-
tropic, antagonistic platelet activating factor, antioxidant, 
metabolic, anti-apoptotic, neuroprotective, and receptor as 
well as (neuro-) transmitter modulating properties [8–11]. 
GBE may also increase cerebral blood flow microcircula-
tion and reduce vascular permeability [11].
Older people with MCI can show deficits in cerebral 
blood flow [12]. Particularly, reduced cerebral blood flow in 
the frontal lobe was reported to be significantly associated 
with impaired gait performance (i.e. decreased gait veloc-
ity, increased gait variability) [13]. Since GBE improves 
cerebral microcirculation, it may also improve circulation 
in the prefrontal cortex [14], which may, in turn, improve 
executive functions, and thus gait stability.
This study aimed to elucidate the effects of GBE on 
spatio-temporal gait parameters during single and dual-
task walking in MCI patients. We hypothesised that MCI 
patients treated with GBE will show a change in gait sta-
bility in dual-task walking compared to those MCI patients 
treated with placebo. Primary and secondary endpoints 
were gait velocity and stride time variability in dual-task 
walking conditions, respectively. In addition, compliance to 
study medication and safety were evaluated.
Methods
Study framework
Fifty older patients diagnosed with MCI and associated 
dual-task-related gait impairment participated in this ran-
domised, double-blind, placebo-controlled, exploratory 
phase IV drug trial. This single-centre study took place at 
the University of Basel Hospital, Division of Acute Geri-
atrics, Switzerland. Patient recruitment occurred between 
January 2010 and February 2014. Study approval was 
obtained from the local ethics committee Basel (EKNZ, 
formerly EKBB, reference number 289/09) and the Swiss 
agency for the authorisation and supervision of therapeu-
tic products (Swissmedic, reference number 2009DR4255). 
All procedures were in accordance with the Declaration 
of Helsinki (1975) and Good Clinical Practice guidelines. 
This study was registered at clinicaltrials.gov (identifier 
NCT01046292).
Participants
Patients of the Memory Clinic and Basel Mobility Center 
were included if they met the following criteria: (1) aged 
50–85 years, (2) German-speaking, (3) completed elemen-
tary school, (4) impaired executive functions defined as a 
reduction in gait velocity of ≥10% during dual-task com-
pared to single-task walking [15], (5) no dementia accord-
ing to International Classifications of Diseases 10 and 
Diagnostic and Statistical Manual of Mental Disorders 
IV, (6) MCI according to Winblad et  al. [12], (7) written 
informed consent prior to inclusion, and (8) nihil obstat 
from the participants’ private physician.
The exclusion criteria were: (1) current drug treat-
ment with antipsychotic or warfarin-like drugs, (2) intake 
of GBE currently or during the last 6 months, (3) known 
hypersensitivity to GBE or its constituents, (4) diagnosed 
psychiatric disorders such as severe clinical depression, 
(5) impaired gait due to orthopaedic (e.g. hip joint replace-
ment) or neurologic disorders (e.g. Parkinson’s disease), (6) 
severe medical conditions (i.e. chronic renal insufficiency), 
(7) participation in a clinical intervention study within the 
previous 2 months, (8) use of a walking aid, and (9) habit-
ual gait velocity <100 cm/s.
Randomization and blinding
Patients were randomly allocated to either the GBE inter-
vention group (IG) or the placebo control group (CG) at 
a ratio of 1:1. The randomization was conducted indepen-
dently by an experienced study pharmacist at the University 
of Basel Hospital pharmacy to ensure that all investigators 
and participants remained blinded. Permuted block rand-
omization (block sizes 2n = 5) were used to ensure numbers 
were evenly distributed among groups.
Study design
At the first on-site visit (V1), patients signed the informed 
consent form, were randomised to either the IG or CG, and 
received their study medication. Gait analysis previously 
performed during diagnostic assessment served as base-
line. After three (V2), six (V3) and 12 (V4) months, on-site 
visits for clinical assessment of gait, compliance to study 
medication, changes in comorbidity and concomitant medi-
cation, and safety were performed. Between these clinical 
visits, monthly follow-up telephone calls were performed to 
update comorbidity, concomitant medication, and safety.
Intervention
Patients allocated to the IG received standardised GBE LI 
1370  (Symfona® forte 120  mg; 25% standardised flavone 
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glycoside, 6% terpene lactone content) for 6 months while 
CG patients received identically appearing placebo cap-
sules (same pharmaceutical excipients, colour and size of 
capsule). Both GBE and placebo were produced and sup-
plied by Vifor SA, Villars-sur-Glâne, Switzerland, and 
repacked, labelled and stored at the University of Basel 
Hospital pharmacy according to Good Manufacturing Prac-
tice annex 13.
At V1 and V2, patients received enough study medica-
tion for 3 months plus a reserve (19 blisters, 190 tablets). 
After V3, a 6-month open-label phase with identical GBE 
dosage (36 blisters, 360 tablets) in both groups followed. 
The study medication dose was one capsule taken twice-
daily with meals. Omitted morning and evening doses were 
allowed to be taken until noon and midnight, respectively. 
Compliance was measured by patients’ empty blisters and 
capsules returned at V2, V3, and V4.
Gait analysis
Gait analyses were performed using a 10-m electronic, 
pressure-sensitive walkway  (GAITRite® Gold and Plati-
num, CIR Systems, Sparta, NJ, USA). Testing was in 
accordance with the European guidelines for clinical appli-
cations of spatio-temporal gait analysis in older people 
[16]. The  GAITRite® system was reported sensitive to rel-
evant gait changes in older people with and without MCI 
[17–19]. Quantitative gait analysis with the  GAITRite® sys-
tem was shown to be feasible and reliable with strong con-
current validity [19]. A further description of the applied 
system and gait analysis is available elsewhere [20].
Patients were verbally instructed to perform a single-
task (walk at their habitual self-selected gait velocity), and 
to perform both a working memory (habitual gait velocity 
while counting backwards out loud from 50 by twos) and 
a semantic memory (habitual gait velocity while naming 
animals out loud) dual-task in a randomised order to avoid 
potential learning effects. Such dual-task paradigms are 
used to investigate motor-cognitive interference between 
walking and an attention-splitting task. Motor-cognitive 
interference, often described as gait irregularity during 
dual-task conditions, is an indicator for decline in gait con-
trol [21].
The following spatio-temporal gait parameters were 
obtained: gait velocity (cm/s), cadence (steps/min), base 
of support (cm), and stride time variability (%). Variability 
was quantified as coefficient of variation [CV = (standard 
deviation/mean) × 100] [16].
Clinical and safety assessment
The following data were assessed by trained and expe-
rienced research staff during the on-site study visits: age, 
gender, body height and mass, body mass index, blood 
pressure, medication and comorbidities. The timed up 
and go (TUG; the time it takes to rise from a chair with 
armrests, walk 3 m at usual speed, turn, walk back, and sit 
down again) [22] and the stops walking when talking test 
(if stopped walking to answer a simple question) [23] were 
performed to assess baseline mobility. Safety was assessed 
by adverse events and serious adverse events for all patients 
according to the Major Diagnostic Categories (http://
health.utah.gov/opha/IBIShelp/codes/MDC.htm).
Statistical analyses and sample size
The sample size was chosen pragmatically for this explora-
tory trial based on clinical, financial and time considera-
tions. Statistical analyses were conducted with data from 
all study participants following the intention to treat prin-
ciple. Baseline characteristics and parameters from all gait 
analyses were described using either mean and standard 
deviation or frequency and percentage. Student’s t tests for 
continuous variables with normal distribution, Chi-square 
test for nominal data, and Mann–Whitney U test for ordi-
nal or continuous data without normal distribution were 
used to determine differences between the IG and CG at 
baseline. Continuous variables were analysed with a mixed 
model for repeated measurements. Treatment group visit 
and interaction between treatment groups were used as 
fixed factors in the model; baseline assessment was used as 
a covariate. Effect sizes (Cohen’s d) were determined with 
values of ≤0.49 indicating small, 0.50 to ≤0.79 medium, 
and ≥0.80 large effects [24]. The two-sided alpha level was 
5%. P values were adjusted for multiple testing using the 
Benjamini-Hochberg correction and considered significant 
when ≤0.05 [25]. Analyses were performed with SAS ver-
sion 9.3 (SAS Institute, Cary, NC, USA).
Results
The flow of patients through this trial is illustrated in Fig. 1. 
Baseline characteristics showed no significant between-
group differences for age, gender, anthropometric vari-
ables, blood pressure, number of drugs and comorbidities, 
and TUG scores (Table 1). Patients who dropped out dur-
ing the blinded treatment phase (n = 7) had a significantly 
lower TUG score compared to participants who completed 
the study (8.7 ± 1.1 vs. 10.1 ± 1.7, p = 0.042). There were 
no statistically significant differences regarding spatio-tem-
poral gait parameters and anthropometric or medical varia-
bles between dropouts and completers. Compliance rates of 
the patient sample were 93 ± 6% (n = 37, range 63–100%) 
at V2, 89 ± 11% (n = 32, 58–100%) at V3, and 92 ± 12% 
(n = 31, 44–100%) at V4.
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Effectiveness of the intervention
Table  2 displays spatio-temporal gait parameters and 
between-group differences. During habitual gait as single 
task there were no statistically significant group differences 
in any of the spatio-temporal parameters during the blinded 
treatment phase. Compared to the CG, cadence increased 
significantly in the IG in the working memory dual-task 
during the blinded treatment phase (p = 0.019, d = 0.71). 
There were no statistically significant group differences in 
dual-tasking for other spatio-temporal gait parameters in 
this time period (Fig. 2a–d).
The separate time effect analyses for the IG showed a 
statistically significant improvement for cadence during the 
working memory dual-task (p = 0.019, d = 0.34). There was 
a numerical non-significant trend in the IG for improve-
ment/maintenance of velocity, cadence and stride time vari-
ability in the single and both dual-task conditions while the 
CG deteriorated in those spatio-temporal parameters during 
the blinded treatment phase (except base of support which 
increased in both groups across all conditions).
Safety
A total of 141 adverse events were reported: 73 adverse 
events in 23 IG patients and 68 adverse events in 19 CG 
patients. There were 29 musculoskeletal system/connec-
tive tissue, 18 infectious, 18 skin/subcutaneous tissue, 17 
multiple significant trauma, 13 ungroupable (i.e. hot flushes 
or sleep disorder), 12 digestive system, 8 eye, 6 kidney/
urinary tract, 5 ear/nose/mouth/throat, 5 nervous system, 
4 blood/-forming organs/immunological, 3 respiratory sys-
tem, and 3 endocrine/nutritional/metabolic system adverse 
events. There was no significant difference in the incidence 
of adverse events between groups (p = 0.468). The study 
physician rated 112 adverse events of mild and 29 adverse 
events of moderate severity and none were related to study 
medication.
A total of 13 serious adverse events were reported: 
7 serious adverse events in 4 IG patients and 6 serious 
adverse events in 5 CG patients. The serious adverse events 
included nasal septum surgery, diverticula, suspected coro-
nary heart disease, pancreatitis, symptomatic cholecys-
tolithiasis, inguinal hernia, knee arthroscopy, commotio 
cerebri, coxarthrosis, antral gastritis, projectile vomiting, 
normal pressure hydrocephalus and transient ischemic 
attack. There was no significant difference in the incidence 
of serious adverse events between groups (p = 0.358). All 
serious adverse events were nonfatal and not related to 
study medication.
Discussion
Our study findings suggest that 120  mg of standard-
ised GBE twice-daily during at least 6  months may 
improve dual-task-related gait performance in patients 
with MCI. Although not in agreement with our 
Pre-screening for eligibility
GBE intervention group (n = 25) 
6 months GBE
+ 6 months GBE
Placebo control group (n = 25)
6 months placebo
+ 6 months GBE
Neuropsychological, medical and gait assessments 
at Memory Clinic and Basel Mobility Center (baseline) 
Informed consent and randomization
Post 3 months assessments
(clinical, gait, safety)







pen-label Post 12 months assessments 
(clinical, gait, safety)
Dropouts (n = 1)
Personal reasons (n = 1)
Dropouts (n = 7)
Medical problems (n = 3)
Personal reasons (n = 1)
Non-compatibility (n = 1)
Non-effectiveness (n = 1)
Fear of side effects (n = 1)
Fig. 1  Study design flow chart (GBE Ginkgo biloba extract)
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hypothesis, working memory dual-task-related gait cadence 
significantly increased in the IG compared to the CG after 
6  months of treatment compared to baseline. According 
to Cohen [24], the magnitude of the observed finding was 
classified as medium-sized effect. This finding was unex-
pected, because previous studies in older people treated 
with cognitive enhancers [26] clearly showed intervention-
induced changes in gait parameters such as gait velocity 
Table 1  Patients’ 
characteristics at baseline 
(mean ± standard deviation)
GBE Ginkgo biloba extract
a Categories affecting less than n = 1 (2%) were not displayed (hepatobiliary system, pancreas; male repro-
ductive system)
b Categorised according to Major Diagnostic Categories. All patients were diagnosed with mild cognitive 
impairment; categories affecting less than n = 1 (2%) were not displayed (antiarrhythmics, antiemetics, 
antihistamines, antivirals, decongestants, diuretics, expectorants)
Characteristics Total (N = 50) GBE intervention 




Age (years) 68.5 ± 8.4 67.8 ± 8.3 69.2 ± 8.6
Gender, female; n (%) 25 (50) 15 (60) 10 (40)
Height (cm) 171.0 ± 10.3 167.9 ± 9.6 174.0 ± 10.2
Weight (kg) 76.1 ± 13.1 73.6 ± 12.7 78.7 ± 13.3
Body mass index (kg/m2) 26.0 ± 3.9 26.1 ± 4.3 25.9 ± 3.5
Systolic blood pressure (mmHg) 140 ± 15 142 ± 15 139 ± 15
Diastolic blood pressure (mmHg) 77 ± 9 76 ± 8 78 ± 10
Number of  drugsa 5.2 ± 3.4 5.3 ± 3.1 5.0 ± 3.8
Analgesics, n (%) 16 (32%) 9 (36%) 7 (28%)
Antacids, n (%) 6 (12%) 6 (24%) 0 (0%)
Anticoagulants and thrombolytics, n (%) 9 (18%) 5 (20%) 4 (16%)
Antidepressants, n (%) 11 (22%) 6 (24%) 5 (20%)
Antihypertensives, n (%) 24 (48%) 10 (40%) 14 (56%)
Anti-inflammatories, n (%) 3 (6%) 1 (4%) 2 (8%)
Bronchodilators, n (%) 6 (12%) 3 (12%) 3 (12%)
Hormones, n (%) 10 (20%) 6 (24%) 4 (16%)
Laxatives, n (%) 2 (4%) 2 (8%) 0 (0%)
Sleeping drugs, n (%) 11 (22%) 6 (24%) 5 (20%)
Vitamins, n (%) 24 (48%) 12 (48%) 12 (48%)
Other, n (%) 16 (32%) 8 (32%) 8 (32%)
Number of  comorbiditiesb 6.3 ± 1.7 6.4 ± 1.8 6.1 ± 1.6
Nervous system, n (%) 26 (52%) 12 (48%) 14 (%)
Eye, n (%) 8 (16%) 5 (20%) 3 (%)
Eear, nose, mouth, throat, n (%) 17 (34%) 6 (24%) 11 (%)
Respiratory system, n (%) 28 (56%) 14 (56%) 14 (%)
Circulatory system, n (%) 32 (64%) 17 (68%) 15 (%)
Digestive system, n (%) 18 (36%) 10 (40%) 8 (%)
Musculoskeletal system, connective tissue, n (%) 39 (78%) 22 (88%) 17 (%)
Skin, subcutaneous tissue, breast, n (%) 4 (8%) 3 (12%) 1 (%)
Endocrine, nutritional, metabolic system, n (%) 46 (92%) 22 (88%) 24 (%)
Kidney, urinary tract, n (%) 27 (54%) 11 (44%) 16 (%)
Blood/-forming organs, immunological, n (%) 19 (38%) 11 (%) 8 (%)
Infectious, parasitic; n (%) 3 (6%) 2 (%) 1 (%)
Alcohol/drug use, induced mental disorder; n (%) 4 (8%) 3 (%) 1 (%)
Factors influencing health status, n (%) 2 (4%) 2 (%) 0 (%)
Multiple significant trauma, n (%) 2 (4%) 1 (%) 1 (%)
Ungroupable, n (%) 36 (72%) 19 (%) 17 (%)
Timed up and go test (s) 9.9 ± 1.7 9.9 ± 1.9 9.9 ± 1.4
Stops walking when talking, yes; n (%) 2 (4%) 0 (0%) 2 (8%)
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and stride time but not cadence. Regarding the observed 
increase in cadence, a possible explanation could be that 
GBE might have had an impact on memory performance, 
a common clinical indication of GBE [11], which is asso-
ciated with gait rhythm [27]. Gait rhythm is related to the 
rhythmic component of counting which in turn may have 
influenced the walking pattern (i.e. cadence) under the 
working memory dual-task condition [28]. The significant 
increase of working memory dual-task-related gait cadence 
is of relevance, because in contrast to other targeted 
interventions (e.g. exercise) [29], this non-targeted GBE 
intervention improved dual-task walking. The small-to-
moderate effect sizes (d = 0.01–0.71) were lower compared 
to an exercise intervention (i.e. resistance and functional 
training) reporting improvements in various gait parameters 
(d ≥ 0.80) [30]. However, methodological differences may 
account for the observed differences in findings between 
studies. While Schwenk et  al. [30] conducted their study 
with demented patients and under single-task walking 
conditions only, the present study was realized with older 























































































Fig. 2  a–d Group comparison of spatio-temporal gait parameters at baseline and post 3, 6 and 12 months (SE Standard error)
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people suffering from MCI and under single- as well as 
dual-task walking conditions.
Mean compliance rates were high with 91% over the 
12-month intervention period. This is in line with previous 
GBE trials which showed comparable levels of treatment 
compliance of 84% [31] and 95% [32]. In the current study, 
141 AEs in 42 patients and 13 SAEs in 9 patients were 
reported, a ratio similar to a randomised controlled GBE 
trial by Napryeyenko et  al. [33]. However, comparison of 
tolerability and safety data among clinical studies with 
GBE is difficult, because they are dependent on patient 
population, intervention duration and dosing regimens 
which are often scarcely documented [34].
Gait velocity is a vital clinical marker for functional sta-
tus and global health (i.e. disability, chronic disease, physi-
ological decline, cognitive impairment, falls, mortality) 
[35–37] in older people [38, 39]. Older people with slow 
gait velocity have higher rates of morbidity and mortality 
than those of the same age with normal gait velocity [36, 
40]. Previous research indicated that a gait velocity of at 
least 100 cm/s is required for unimpaired walking [40, 41] 
while values below 100 cm/s were associated with limita-
tions in activities of daily living [39]. In the current study, 
all patients started with good functionality, since all had a 
gait velocity of >100  cm/s during usual walking at base-
line. This may partly explain why there was a numerical 
non-significant trend but not the expected increase in habit-
ual gait velocity in the IG.
While walking under dual-task, a decrease in gait veloc-
ity of up to 10% of the gait velocity during habitual walking 
is considered normal. Post six months the IG had a working 
memory (IG: +5%, CG: 0%) and semantic memory (IG: 
−3%, CG: −6%) dual-task-related gait velocity decrease of 
less than 10% of their habitual gait velocity. The differences 
in mean gait velocity of 11.7 cm/s for the working memory 
and 7.2  cm/s for the semantic memory dual-task between 
IG and CG at V3 would represent meaningful small-to-
moderate clinical effects [42]. This implies that GBE may 
have had a positive effect on gait velocity, and thus inde-
pendent mobility and general well-being. In addition, our 
study was able to confirm earlier findings of older people 
with MCI who decreased their mean velocity during habit-
ual walking when dual-tasking [17], which was probably 
due to additionally involved cognitive resources [3]. Fur-
ther in line with previous research, gait velocity decreased 
as dual-task complexity increased from working to seman-
tic dual-tasking [43].
Besides gait velocity, older people tend to decrease dual-
task-related cadence with increasing age [3, 44]. Higher 
cadence has been interpreted as an adaptive strategy to 
spend less time in the unstable single support phase or an 
alternative to increasing step length when walking faster 
[45]. The results of the present study showed increases 
in cadence for the IG in working memory dual-task. This 
result suggests that patients with MCI in the IG adapted 
their gait pattern by performing more steps per minute, 
and therefore spending more time in a stable double sup-
port phase. In contrast, the CG adopted a gait pattern simi-
lar to that of more frail older people by decreasing cadence 
during the blinded treatment phase [44]. The normal range 
of mean cadence lies between 102 and 113 steps/min (age 
group 70–74) [46] which was better achieved by the IG 
than the CG.
To avoid slips, trips, and missteps, a person is required 
to step safe by keeping the centre of mass within the base 
of support [47]. Increases in base of support, especially 
when dual-tasking, have been associated with greater body 
sway in older people [48]. This may further lead to loss of 
balance in the mediolateral plane [49], falls to the side and 
related injuries (e.g. femoral neck fracture). In the current 
study, base of support increased in the IG and CG in all 
conditions. Previous research discussed such gait pattern 
adaptations as indicative for precautious gait [50] and fear 
of falling, an important fall risk factor [51]. Base of sup-
port values were comparable to previous studies in similar 
populations (between 7.9 and 10.7 cm) [46, 52].
In previous research, significantly low or high stride 
time variability has been associated with gait unsteadiness 
[53], gait instability [54] and fall risk in older people [55]. 
A stride time variability threshold of CV >4% for usual 
walking and CV >10% for dual-tasking was proclaimed 
for older people [56] while patients with MCI showed even 
higher CVs for stride time variability [57]. This is in line 
with findings of the current study which showed stride time 
variability values around CV 2% for usual walking, CV 
7% for working dual-task and CV 10% for semantic dual-
task. However, during the blinded treatment phase the IG 
decreased/maintained stride time variability while the CG 
increased stride time variability. In MCI patients we would 
generally expect a worsening of dual-task-related stride 
time variability over time due to progressing cognitive 
decline. Although values for stride time variability were 
above normal range in both groups, the decrease/mainte-
nance in IG versus the increase in CG may indicate a posi-
tive GBE-related effect. In other words, the IG seemed to 
have a more regular gait [58, 59] and superior executive 
function compared to the CG [53, 60, 61].
In this study, the most pronounced effects on spatio-tem-
poral gait parameters were seen during the blinded treat-
ment phase in favour of the IG which suggests exposure-
dependence. Due to the fact that the CG deteriorated in all 
spatio-temporal gait parameters it can be concluded that 
there was no placebo effect. In the open-label phase, the IG 
was able to maintain most effects on the spatio-temporal 
gait parameters which indicate that long-term GBE intake 
over 1  year may be required to elicit more pronounced 
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effects [32]. However, the impact of GBE on the CG during 
the open-label phase is equivocal. One possible explanation 
could be that GBE treatment should start at an early stage 
of MCI, because treatment-free progression of the disease 
for 6 months may lower a potential effect.
The main strength of this study is to provide primary 
data on GBE and its effect on spatio-temporal gait param-
eters in patients with MCI to the literature. In addition, the 
extensive eligibility criteria ensured that a coherent patient 
sample was recruited. Furthermore, patient compliance was 
very high which can be partly attributed to the 6-month 
open-label phase and associated cost-free GBE provision. 
However, the study had several limitations. The gait analy-
ses were conducted in a highly standardised laboratory set-
ting and may have limited applicability to walking in daily 
life situations. No distinction was made between amnestic 
and non-amnestic MCI which may have had an influence 
on interpretation of dual-task performance. Future stud-
ies with larger patient collectives should be conducted to 
increase power.
Conclusion
In conclusion, standardised GBE showed the potential to 
improve dual-task-related gait performance (i.e. cadence) 
in MCI patients. The observed medium-sized effects in 
gait improvements add to the understanding of the self-
reported unspecified improvements among MCI patients 
when treated with standardised GBE. Results of this study 
may lead to better treatment strategies for older people 
with MCI to improve gait performance, mobility and daily 
functioning.
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